Clinical Trial Details
— Status: Active, not recruiting
Administrative data
| NCT number |
NCT01433601 |
| Other study ID # |
DotArv_Vietnam |
| Secondary ID |
|
| Status |
Active, not recruiting |
| Phase |
N/A
|
| First received |
September 9, 2011 |
| Last updated |
September 13, 2011 |
| Start date |
August 2007 |
| Est. completion date |
November 2011 |
Study information
| Verified date |
September 2011 |
| Source |
Karolinska Institutet |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
Vietnam: Ministry of Health |
| Study type |
Interventional
|
Clinical Trial Summary
This project aims to assess different antiretroviral treatment strategies, optimally
controlled and conventional, in relation to drug resistance and virological treatment
failure. A Randomised Controlled trial (RCT) where Vietnamese HIV+ patients with CD4+
T-cells <200/ul are randomized into either enhanced treatment support (ETS) through peer
supporters or The National AIDS Control Program recommended self supervised treatment (SST).
The treatment strategies will be assessed and compared in relation to treatment adherence
and drug resistance development with virological treatment failure as primary endpoint. The
results from this project will lead to an increased knowledge in relation the impact of
treatment support on adherence, virological suppression and resistance development and have
an impact on HIV treatment policies in low income settings globally.
Description:
Aim To study the impact of patient support on selective drug pressure, defined by
semi-quantitative assessments of adherence, on the viral suppression and resistance
development through a randomised controlled trial of HIV positive patients randomised in
enhanced treatment support (ETS) and self supervised treatment (SST).
Specific Objectives
1. To create a study population 600 HIV+ patients with CD4+ T-cell count of <200/ul and
randomize in two different treatment cohorts, enhanced treatment support (ETS) and
conventional self-supervised treatment (SST).
2. To monitor the patients using semi-quantitative assessments of adherence, clinical
status including clinical examinations (every 3 months), viral load and CD4+ T-cell
count (every 6 months) during 24 months with virological treatment failure as primary
endpoint.
3. To compare the ETS and SST cohorts with respect to the primary endpoint, virological
treatment failure, in relation to the semi-quantitative assessments of adherence and to
analyse the mechanism of selective drug pressure for the development of resistance
including resistance in minor viral subpopulations.
4. To conduct a cost effectiveness assessment comparing ETS and SST with respect to the
labour and infrastructural cost, virological treatment failure and change to second
line therapy.
The study is conducted in Quang Ninh Province, the area hardest hit by the HIV epidemic in
Vietnam with a known HIV+ prevalence above 1%. A study population of 600 HIV+ patients with
CD4+ T-cell count of <200 are being be recruited in four districts, Ha Long, Uong Bi, Yen
Huong and Dong Trieu. Each HIV+ person is examined according to WHO guidelines. HIV+ persons
receive a complete physical examination, clinical staging of HIV infection, opportunistic
infections including HBV, HCV and tuberculosis. Laboratory testing will include Full blood
count, CD4+ T-cell count, viral load using the affordable and simple ELISA based ExaVirR
viral load test (http://www.cavidi.se), liver enzymes, PAP smear and pregnancy test for
women. If indicated (e.g. prolonged cough) chest X-ray, sputum microscopy for AFB are done.
Opportunistic infections in HIV+ patients are treated according to national guidelines. HIV+
persons receive counselling including information about the disease and the plan for care
and treatment, follow-up visits, nutrition and living, prevention of HIV transmission
including safe sex, harm reduction measures, the use of birth control methods and prevention
of mother to child HIV transmission.
Inclusion and exclusion criteria's are described below. The patients will be randomised into
two equally large cohorts, receiving either of two different treatment strategies a)
enhanced treatment support (ETS) (described below) and Self-supervised treatment (SST).
Co-infections are assessed, diagnosed and the treatment adjusted according to the national
guidelines for such situations. The patients are studied with respect to: (i) virological
treatment failure, (ii) adverse effects. (iii) patient's adherence to treatment strategy.
First drug regimen for all patients including stavudine, lamivudine, nevirapine or efavirenz
dosages, follow up for adverse effects and regimen alteration are done according to national
guidelines. The health care workers are trained in regular monitoring of patients and
implementation of optimal treatment strategy. All procedures and treatment will follow the
national guidelines. Follow up consultations including physical examinations and tests are
done every 3 month.
The tests will include full blood count, CRP, electrolytes, liver enzymes as well as other
indicated. Viral load are monitored every 6 month and CD4+ T-cell count every 12 month.
The number of patients needed for each arm of the experiment was estimated assuming a
difference between arms of 15 percent units for treatment failure and corresponding baseline
percentage of 20%. Requiring a power of 80% and a significance level of 5% the necessary
number is about 300 per arm. Inflating the size by 30% to compensate for expected loss to
follow up the investigators get just under 300 patients per arm. The assumptions about
differences are based on the following: a) Differences larger than 10% units in virological
treatment failure are indications for review and modification of treatment strategies; b)
group differences in virological treatment failure less the 20% are unlikely to lead to
policy changes in Vietnam. The discussion above uses a binary variable like failure/no
failure. Performing analysis on quantitative variables like CD4 T-cell readings, which are
more informative, will in some cases have considerably higher power than the corresponding
binary.
In the ETS strategy an "internal supporter", family member or other person trusted by the
patient, is trained to fill in a checklist whether the drugs has been taken and if this was
observed. An"external supporter" - a peer selected PLWHA visit the patient twice weekly the
first two months. The external supporter follows a checklist and ask about general well
being, psychological problems or adverse drugs reactions as well as go through the adherence
since last visit, using the internal supporter checklist. If the adherence is good, the
number of visits are decreased to once weekly after two months, if not, the number of visits
are intensified. If there are any symptoms of opportunistic infections, immunological
reconstruction syndrome or adverse drug reactions the patient are refered for medical
checkup.. In SST the patient will self be responsible to take the drugs. At initiation
treatment counseling are provided. In both groups the drugs are provided in a pre-packed
dosage form for easy remembering and counting of the pills.
The patients are followed for 24 months and monitored through clinical examination (each 3
months), viral load in plasma (each six months), CD4- T-cell counts (each 6 months) and
assessment of well-being (every 3 months). Adherence among patients are assessed using
Contextualised Adult AIDS Clinical Trials Group (AACTG) Adherence Instruments (Chesney et
al, 2000). AACTG Adherence Instruments consists of two questionnaires and the first
questionnaire is specifically developed to be used for baseline assessment of adherence. The
second questionnaire version is developed for assessment of adherence during follow-up
visits. Adherence are assessed using the AACTG Adherence Instruments every third month in
both the ETS and SST groups. One person is present at the clinic to answer questions
regarding the questionnaire and provide help if necessary. Adherence is also measured by
pill count conducted by the External supporters, enabling calculation of the proportion of
drugs remaining out of the total amount of prescribed drugs. Assessment of side effects
according to WHO suggested monitoring and management of ARV drugs are done together with the
clinical examination each three months.
The primary endpoint is virological treatment failure defined as a viral load of 1 fg
reverse transcriptase activity/ml, corresponding to 200 copies/ml, at 1 year and 2 years
after starting treatment. Drug Resistance is determined using a selective real-time PCR for
the detection of the critical mutations in the RT-gene, as a marker for whether virological
treatment failure that occurs with wild-type virus or resistant virus. The secondary
endpoints immunological treatment failure (no rise in CD4+ T-cell count at 1 year) and
clinical treatment failure as defined by a new AIDS defining illness or death due to
HIV/AIDS (including TB and opportunistic infection) after starting treatment.
Costing of the two different strategies will be carried out by collecting monetary data of
expenses of drugs, test, allowance and other expenses from perspective of the HIV/AIDS
treatment provider during ART. The investigators follow the basic principles of
activity-based costing by identifying all activities necessary to provide the EST and SST
and then calculate the costs of carrying out each activity. Costs for each activity comprise
recurrent and capital costs, direct and indirect costs. Recurrent costs are the routine
costs of resources that are consumed within a year, i.e., non-capital items such as labor
and medical supplies. Capital costs represent the annual portion of the cost of durable HIV
Sida DOTARV assets. Effectiveness will be measured by percentages of patients with
virological treatment failure defined as Viral Load>400 copies/ml.
The statistical analysis mainly consists in the comparison between the two groups with
respect to the defined primary endpoint, virological treatment failure, and possibly the
secondary endpoints immunological treatment failure and clinical treatment failure, in
relation to the semi-quantitative assessments of adherence. Basically standard statistical
methods will be used. Regression models with outcome as the dependent variable and a group
indicator together with person characteristics as independent variables will be the main
approach. For binary outcomes, logistic regression will be used. Attention has to be paid to
the particular, often skewed, distributions of variables like CD4+ T-cell counts and viral
load. Transformations or the use of non-parametric approaches are likely to be necessary if
such measures are not dichotomised and used in linear regression. The correlation between
drug resistance to the used drugs (stavudine, lamivudine, nevirapine) and adherence will be
statistically analysed in order to study whether the basic mechanisms of selective drug
pressure result in a concave or bell-shaped resistance - adherence relationship, for these
drugs during ETS or SST in a low-income setting.
The investigators will strictly comply with widely recognized international texts and codes
of practice including the Helsinki agreement. In this project one patient cohort will
receive ETS and the other SST. Both the OTC and SST cohorts will be encouraged to proceed
regularly with their drug treatment and to present difficulties that they may encounter in
doing so. For the project period, the project will meet the costs of ARV for the cohorts.
Patients' biological samples are collected and used only after written consent. All
specimens are coded to protect the identity of patients and to ensure confidentiality.
Patients are recruited in a consecutive manner without regard to race or other exclusion
considerations. Confidentiality is assured by using codes for patient identification, and
confidentially laws will be strictly observed when processing human clinical information. No
patient identifying information will be published or available after the requisite clinical
data have been collected, and consent will be obtained for the use of all data and tissues.
Data is accessible only to members and coordinators of the tissue procurement facility and
research team, under approved guidelines.
